Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXA-CoV2-3.3 vs COMIRNATY in Adults Previously Immunized Against COVID-19
NCT06672055Phase 2Active, not recruiting
- Sponsor
- Vaxart, Inc.
- Start
- Oct 2024
- Primary completion
- May 2027
- Modality
- Vaccines & Immunotherapeutics, Adenoviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of VXA-CoV2-3.3 in coronavirus disease 2019 (COVID-19), sponsored by Vaxart, Inc.. Started Oct 2024; status: active, not recruiting.
02
Drugs
VXA-CoV2-3.3
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06672055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672055.